All the news Showing 10 of 44 articles from: Genotype 3Get an RSS feed of these articles Show All news infohep newsEditors' picks from other sources FDA OK's BMS Daklinza (Daclatasvir) to Treat Hep C Genotype 3 Manual Items / 27 July 2015 Shortening hepatitis C treatment to 6 weeks effective but not perfect for easier-to-treat patients Keith Alcorn / 13 May 2015 Shortening hepatitis C treatment to 6 weeks for easier-to-treat patients without cirrhosis does not greatly reduce the efficacy of hepatitis C treatment for people with genotype 1 infection, according to results of a ... Sofosbuvir plus pegylated interferon/ribavirin is highly effective for people with hard-to-treat genotype 3 hepatitis C Liz Highleyman / 29 April 2015 A throwback regimen of sofosbuvir (Sovaldi), ribavirin and pegylated interferon taken for 12 weeks cured 93% of people with hepatitis C virus (HCV) genotype 3 – substantially more than sofosbuvir plus ribavirin alone ... NICE consults on draft guidance recommending ledipasvir-sofosbuvir (Harvoni) for treating chronic hepatitis C NICE / 04 March 2015 Daclatasvir + sofosbuvir demonstrates good cure rate for genotype 3 hepatitis C Liz Highleyman / 04 December 2014 An all-oral combination of daclatasvir (Daklinza) plus sofosbuvir (Sovaldi), taken for 12 weeks, produced sustained virological response rates of 90% for previously untreated patients and 86% for prior non-responders with hepatitis C virus ... Sofosbuvir + GS-5816 for 12 weeks shows high HCV cure rates, but 8 weeks is less effective for some patients Liz Highleyman / 02 December 2014 A 12-week oral combination of sofosbuvir plus the experimental NS5A inhibitor GS-5816 demonstrated high sustained virological response rates for people with difficult-to-treat HCV genotype 3 and other genotypes, according to phase 2 study ... Sofosbuvir + ribavirin cures hepatitis C for more than 80% of people with HIV and HCV co-infection Liz Highleyman / 28 July 2014 An interferon-free regimen of sofosbuvir (Sovaldi) plus ribavirin for 24 weeks led to sustained hepatitis C virological response in 84 to 89% of HIV-positive people with chronic hepatitis C genotypes 1, 2, ... Why Merck Just Spent $4 Billion On New Drugs For Hepatitis C Forbes / 09 June 2014 European liver specialists recommend use of newest hepatitis C drugs Keith Alcorn / 12 April 2014 The European Association for the Study of the Liver (EASL) has issued new guidelines for the treatment of hepatitis C which recommend that wherever possible, patients should be treated with ... Sofosbuvir/ledipasvir is safe and effective for relapsers and hard-to-treat patients Liz Highleyman / 11 April 2014 A co-formulation of sofosbuvir and ledipasvir successfully treated a variety of difficult-to-treat patient populations including people with hepatitis C virus (HCV) genotype 3, people with decompensated cirrhosis and people who were not cured ... ← Prev12345Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive